ArticleEuropean journal of clinical investigation2020
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.
Article in European journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2022Pooled it
- Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.European journal of clinical investigation · 2021Pooled it
- Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.Critical reviews in oncology/hematology · 2021Pooled it
- Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review.JCO global oncology · 2021Pooled it
- The Effects of COVID-19 on Cancer Care Provision: A Systematic Review.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.Frontiers in oncology · 2022Review
- The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.Mediterranean journal of hematology and infectious diseases · 2022Review
- Emerging issues related to COVID-19 vaccination in patients with cancer.Oncology and therapy · 2021Article
- Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.Science advances · 2021Article
- Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.JCO oncology practice · 2021Article
- Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.JCO global oncology · 2021Article
- Analysis of Anxiety and Depression Status in Patients Undergoing Radiotherapy During the COVID-19 Epidemic.Frontiers in psychiatry · 2021Article
- Cancer patient management strategy in a Cancer Center of Zhejiang, China during the COVID-19 pandemic.BMC cancer · 2020Article
- Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.Oncology and therapy · 2020Article
- Article
- Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy.ESMO open · 2020Observational
- Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.European journal of clinical investigation · 2020Article
- SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.ESMO open · 2020Article
- Updated general recommendations in cancer management during the COVID-19 pandemic in the Philippines.Ecancermedicalscience · 2020Article
- Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?Frontiers in public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDuring COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. MATERIALS AND
methodsBetween 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management.
resultsThe 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned.
conclusionsThese results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.